Skip to main content
Equibles
TVTX logo

TVTX · Travere Therapeutics, Inc. · Metrics

Track TVTX — free

Use TVTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TVTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$50.08 -2.35 (-4.48%) At close · Oct 23
Russell 2000 member Rebalance outlook locked
Market Cap
$4.72B
Shares
94.26M
Volume · Oct 23 2.31M Avg daily vol (3M) 1.7M

TVTX metrics

79 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$50.08
Market cap
$4.72B

Price action

20 metrics
Price change (1W)
+1.0%
Price change (30D)
-17.4%
Price change (3M)
-12.7%
Price change (6M)
+23.7%
Price change (YTD)
+31.1%
Price change (1Y)
+77.9%
Trailing year
Price change (5Y)
+90.6%
52-week high
$67.52
52-week low
$26.79
Change from 52-week high
-25.8%
Change from 52-week low
+86.9%
Annualized volatility
65.4%
Annualized volatility (3M)
43.0%
Beta
1.4
RSI (14D)
33.0
Price vs SMA 50
-17.1%
Price vs SMA 200
+8.5%
Avg volume (3M)
1.70M
Relative volume
1.4
Average dollar volume
$100.74M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
94.26M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
8.9×
reciprocal yield 11.3%
EV / EBITDA
228.7×
reciprocal yield 0.4%
EV / EBIT
—
P / sales
8.0×
reciprocal yield 12.4%
P / book
193.9
reciprocal yield 0.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
51.3
reciprocal yield 1.9%
Earnings yield
-0.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
6.9×
reciprocal yield 14.4%
EV / revenue historical average (5Y)
7.0×
reciprocal yield 14.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-04

Profitability

9 metrics
Gross margin
98.6%
Operating margin
-6.8%
Trailing 12 months
Net margin
-7.4%
Gross profit (TTM)
$583.07M
Operating profit (TTM)
−$40.46M
Net income (TTM)
−$43.46M
Trailing 12 months
Diluted EPS (TTM)
$-0.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$1.26

Growth

11 metrics
Revenue growth YoY
+48.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$591.33M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+5.1%
Year over year · more shares
Revenue CAGR (3Y)
+64.9%
Revenue CAGR (5Y)
+19.9%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-177.2%
Return on assets
-5.4%
Debt / equity
24.6
Current ratio
4.0
EBITDA (TTM)
$22.91M
Free cash flow (TTM)
—
Quick ratio
3.8
Interest coverage
-4.3
Net debt / EBITDA
21.2
Return on invested capital
—
Trailing 12 months
Net cash
−$485.05M
Latest balance sheet
Cash & equivalents
$117.73M
Total assets
$799.36M
Total debt
$602.78M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$92.70M
Capital expenditures (TTM)
$107,000
R&D (TTM)
$227.14M
SG&A (TTM)
$390.57M
Stock compensation (TTM)
$60.66M
R&D / revenue
38.4%
Stock compensation / revenue
10.3%

Ownership (13F)

9 metrics
13F filers
321
13F filer change QoQ
+57
Institutional ownership
113.9%
Conviction holders (share of 13F filers)
3.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+6.4%
Holder tenure
11.3
Price vs estimated holder cost
+115.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.5%

Short interest

3 metrics
Short interest
13.4%
Latest settlement · 7.2 days to cover
Days to cover
7.2d
Short-squeeze score
67 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$80.13M
Insider-sentiment score
57 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1438533 CUSIP 89422G107 13F (30d) 35 filings 35 filers Visit website Investor relations